Citadel Advisors
AMLX icon

Citadel Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Citadel Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.21M Sell
178,686
-232,846
-57% -$3.6M ﹤0.01% 5577
2026
Q1 		$5.72M Buy
411,532
+66,564
+19% +$936K ﹤0.01% 4124
2025
Q4 		$4.17M Buy
344,968
+110,295
+47% +$1.5M ﹤0.01% 4574
2025
Q3 		$3.19M Sell
234,673
-1,008,254
-81% -$9.49M ﹤0.01% 5197
2025
Q2 		$7.97M Sell
1,242,927
-1,514,849
-55% -$7.37M ﹤0.01% 3364
2025
Q1 		$9.76M Buy
2,757,776
+787,072
+40% +$2.8M ﹤0.01% 2877
2024
Q4 		$7.45M Buy
1,970,704
+71,144
+4% +$335K ﹤0.01% 3356
2024
Q3 		$6.15M Buy
1,899,560
+554,742
+41% +$1.25M ﹤0.01% 3619
2024
Q2 		$2.56M Buy
1,344,818
+14,434
+1% +$28K ﹤0.01% 4861
2024
Q1 		$3.78M Sell
1,330,384
-910,501
-41% -$11.9M ﹤0.01% 4401
2023
Q4 		$33M Buy
2,240,885
+1,013,941
+83% +$15.5M 0.01% 1527
2023
Q3 		$22.5M Buy
1,226,944
+413,619
+51% +$8.75M ﹤0.01% 1740
2023
Q2 		$17.5M Buy
813,325
+584,419
+255% +$15.8M ﹤0.01% 2019
2023
Q1 		$6.72M Buy
228,906
+172,149
+303% +$5.98M ﹤0.01% 3340
2022
Q4 		$2.1M Sell
56,757
-750,073
-93% -$26.6M ﹤0.01% 5400
2022
Q3 		$22.7M Buy
806,830
+52,420
+7% +$1.31M 0.01% 1755
2022
Q2 		$14.5M Buy
754,410
+252,774
+50% +$3M ﹤0.01% 2219
2022
Q1 		$6.45M Buy
+501,636
New +$11.3M ﹤0.01% 3696

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Citadel Advisors's AMLX Position: Q2 2026 in Review

Citadel Advisors reduced its Amylyx Pharmaceuticals (AMLX) stake by 57% in Q2 2026, selling an estimated $3.6M and leaving 178,686 shares worth $3.21M. The position accounts for ﹤0.01% of the portfolio, ranked #5577.

Citadel Advisors first reported a position in AMLX in Q1 2022 and has held it in 18 quarters since. The position peaked at $33M in Q4 2023. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Citadel Advisors held 178,686 shares of Amylyx Pharmaceuticals worth $3.21M as of Q2 2026.
  • Citadel Advisors sold 232,846 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $3.6M.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5577 holding.
  • Citadel Advisors first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Citadel Advisors's Amylyx Pharmaceuticals position peaked at $33M in Q4 2023.
  • 207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.